Change from baseline at week 12 | Change from baseline at week 64 | Change from week 12 to week 64 | ||||
---|---|---|---|---|---|---|
Endpoint | Placebo (n = 53) | Sildenafil (n = 50) | Placebo (n = 53) | Sildenafil (n = 50) | Placebo (n = 48) | Sildenafil (n = 43) |
Borg dyspnoea score (LOCF) | ||||||
n | 53 | 49 | 53 | 49 | 47 | 36 |
Median change (range) | 0 (−3, 6) | 0 (−6, 2) | 0 (−3, 7) | 0 (−4, 4) | 0 (−7, 8) | 0 (−2, 4) |
WHO functional class (LOCF), n (%) | ||||||
Worsened 1 class | 1 (2) | 0 (0) | 4 (8) | 5 (10) | 4 (8) | 8 (19) |
No change | 45 (85) | 39 (78) | 34 (64) | 34 (68) | 34 (71) | 28 (65) |
Improved 1 class | 7 (13) | 10 (20) | 15 (28) | 10 (20) | 9 (19) | 3 (7) |
Died | 0 | 1 (2) | 0 | 1 (2) | 0 | 1 (2) |
Missing | 0 | 0 | 0 | 0 | 1 (2) | 3 (7) |
BNP | ||||||
n | 35 | 33 | 24 | 18 | 21 | 21 |
Median change (min, max), pg/mL | 8.0 (−217.5, 254.4) | −1.0 (−436.5, 268.7) | 3.0 (−125.4, 738.0) | 34.3 (−618.2, 1141.8) | −6.1 (−166.9, 652.0) | 20.1 (−643.7, 1218.8) |
N-terminal pro-BNP | ||||||
n | 14 | 19 | 9 | 10 | 9 | 12 |
Median change (min, max), pg/mL | 14.3 (−2227.0, 600.0) | −94.1 (−1277.0, 221.0) | 7.8 (−1761.0, 561.3) | −121.7 (−895.3, 5519.4) | 55.0 (−1029.0, 466.0) | −13.2 (−459.4, 5656.2) |